{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:16:08Z","timestamp":1791918968248,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:00:00Z","timestamp":1559692800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:00:00Z","timestamp":1559692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1038\/s41401-019-0251-7","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T07:03:09Z","timestamp":1559718189000},"page":"1596-1602","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Preclinical PK\/PD model for the combinatorial use of dexamethasone and sulpiride in the treatment of breast cancer"],"prefix":"10.1038","volume":"40","author":[{"given":"Qing-yu","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-sheng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,5]]},"reference":[{"key":"251_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"key":"251_CR2","doi-asserted-by":"publisher","first-page":"324","DOI":"10.6004\/jnccn.2016.0037","volume":"14","author":"WJ Gradishar","year":"2016","unstructured":"Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14:324\u201354. (PMID: 26957618).","journal-title":"J Natl Compr Canc Netw"},{"key":"251_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321:288\u2013300.","journal-title":"JAMA"},{"key":"251_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coph.2016.11.005","volume":"31","author":"G Gu","year":"2016","unstructured":"Gu G, Dustin D, Fuqua SA. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. Curr Opin Pharm. 2016;31:97\u2013103.","journal-title":"Curr Opin Pharm"},{"key":"251_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ctrv.2018.07.004","volume":"69","author":"X Bai","year":"2018","unstructured":"Bai X, Ni J, Beretov J, Graham P, Li Y. Cancer stem cell in breast cancer therapeutic resistance. Cancer Treat Rev. 2018;69:152\u201363.","journal-title":"Cancer Treat Rev"},{"key":"251_CR6","doi-asserted-by":"publisher","first-page":"7386","DOI":"10.1158\/0008-5472.CAN-08-1545","volume":"68","author":"H Gong","year":"2008","unstructured":"Gong H, Jarzynka MJ, Cole TJ, Lee JH, Wada T, Zhang B, et al. Glucocorticoids antagonize estrogens by glucocorticoid receptor-mediated activation of estrogen sulfotransferase. Cancer Res. 2008;68:7386\u201393.","journal-title":"Cancer Res"},{"key":"251_CR7","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1002\/jps.24629","volume":"104","author":"Y Yuan","year":"2015","unstructured":"Yuan Y, Zhou X, Ren Y, Zhou S, Wang L, Ji S, et al. Semi-mechanism-based pharmacokinetic\/pharmacodynamic model for the combination use of dexamethasone and gemcitabine in breast cancer. J Pharm Sci. 2015;104:4399\u2013408.","journal-title":"J Pharm Sci"},{"key":"251_CR8","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/aps.2016.39","volume":"37","author":"LJ Wang","year":"2016","unstructured":"Wang LJ, Li J, Hao FR, Yuan Y, Li JY, Lu W, et al. Dexamethasone suppresses the growth of human non-small cell lung cancer via inducing estrogen sulfotransferase and inactivating estrogen. Acta Pharm Sin. 2016;37:845\u201356.","journal-title":"Acta Pharm Sin"},{"key":"251_CR9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.4161\/cbt.7.7.6099","volume":"7","author":"JH Egberts","year":"2008","unstructured":"Egberts JH, Schniewind B, Patzold M, Kettler B, Tepel J, Kalthoff H, et al. Dexamethasone reduces tumor recurrence and metastasis after pancreatic tumor resection in SCID mice. Cancer Biol Ther. 2008;7:1044\u201350.","journal-title":"Cancer Biol Ther"},{"key":"251_CR10","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/aps.2017.153","volume":"39","author":"J Li","year":"2018","unstructured":"Li J, Chen R, Yao QY, Liu SJ, Tian XY, Hao CY, et al. Time-dependent pharmacokinetics of dexamethasone and its efficacy in human breast cancer xenograft mice: a semi-mechanism-based pharmacokinetic\/pharmacodynamic model. Acta Pharm Sin. 2018;39:472\u201381.","journal-title":"Acta Pharm Sin"},{"key":"251_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/0962935031000096953","volume":"12","author":"M Castro-Caldas","year":"2003","unstructured":"Castro-Caldas M, Mendes AF, Carvalho AP, Duarte CB, Lopes MC. Dexamethasone prevents interleukin-1beta-induced nuclear factor-kappaB activation by upregulating IkappaB-alpha synthesis, in lymphoblastic cells. Mediat Inflamm. 2003;12:37\u201346.","journal-title":"Mediat Inflamm"},{"key":"251_CR12","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-05-2085","volume":"12","author":"A Yano","year":"2006","unstructured":"Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res. 2006;12:3003\u20139.","journal-title":"Clin Cancer Res"},{"key":"251_CR13","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/j.ejca.2012.03.019","volume":"48","author":"MP Ablett","year":"2012","unstructured":"Ablett MP, Singh JK, Clarke RB. Stem cells in breast tumours: are they ready for the clinic? Eur J Cancer. 2012;48:2104\u201316.","journal-title":"Eur J Cancer"},{"key":"251_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.pharmthera.2016.02.008","volume":"160","author":"J Zhao","year":"2016","unstructured":"Zhao J. Cancer stem cells and chemoresistance: the smartest survives the raid. Pharm Ther. 2016;160:145\u201358.","journal-title":"Pharm Ther"},{"key":"251_CR15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bcp.2015.03.013","volume":"95","author":"S Wang","year":"2015","unstructured":"Wang S, Mou Z, Ma Y, Li J, Li J, Ji X, et al. Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cells. Biochem Pharm. 2015;95:98\u2013109.","journal-title":"Biochem Pharm"},{"key":"251_CR16","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2012.03.049","volume":"149","author":"E Sachlos","year":"2012","unstructured":"Sachlos E, Risueno RM, Laronde S, Shapovalova Z, Lee JH, Russell J, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. 2012;149:1284\u201397.","journal-title":"Cell"},{"key":"251_CR17","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1164\/rccm.201207-1180OC","volume":"186","author":"CT Yeh","year":"2012","unstructured":"Yeh CT, Wu AT, Chang PM, Chen KY, Yang CN, Yang SC, et al. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med. 2012;186:1180\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"251_CR18","first-page":"655","volume":"32","author":"M Rzewuska","year":"1998","unstructured":"Rzewuska M. [Sulpiride: the best known atypical, safe neuroleptic drug. Review of literature]. Psychiatr Pol. 1998;32:655\u201366.","journal-title":"Psychiatr Pol"},{"key":"251_CR19","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/aps.2017.24","volume":"38","author":"J Li","year":"2017","unstructured":"Li J, Yao QY, Xue JS, Wang LJ, Yuan Y, Tian XY, et al. Dopamine D2 receptor antagonist sulpiride enhances dexamethasone responses in the treatment of drug-resistant and metastatic breast cancer. Acta Pharm Sin. 2017;38:1282\u201396.","journal-title":"Acta Pharm Sin"},{"key":"251_CR20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3109\/00498254.2012.761741","volume":"43","author":"K Iwanaga","year":"2013","unstructured":"Iwanaga K, Honjo T, Miyazaki M, Kakemi M. Time-dependent changes in hepatic and intestinal induction of cytochrome P450 3A after administration of dexamethasone to rats. Xenobiotica. 2013;43:765\u201373.","journal-title":"Xenobiotica"},{"key":"251_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1248\/bpb.27.77","volume":"27","author":"K Watanabe","year":"2004","unstructured":"Watanabe K, Sawano T, Jinriki T, Sato J. Studies on intestinal absorption of sulpiride (3): intestinal absorption of sulpiride in rats. Biol Pharm Bull. 2004;27:77\u201381.","journal-title":"Biol Pharm Bull"},{"key":"251_CR22","first-page":"179","volume":"36","author":"G Koch","year":"2009","unstructured":"Koch G, Walz A, Lahu G, Schropp J. Modeling of tumor growth and anticancer effects of combination therapy. J Pharm Pharm. 2009;36:179\u201397.","journal-title":"J Pharm Pharm"},{"key":"251_CR23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/bdd.1843","volume":"34","author":"SA Helmy","year":"2013","unstructured":"Helmy SA. Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. Biopharm Drug Dispos. 2013;34:288\u2013301.","journal-title":"Biopharm Drug Dispos"},{"key":"251_CR24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00280-008-0767-x","volume":"63","author":"M Leggas","year":"2009","unstructured":"Leggas M, Kuo KL, Robert F, Cloud G, deShazo M, Zhang R, et al. Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy. Cancer Chemother Pharm. 2009;63:731\u201343.","journal-title":"Cancer Chemother Pharm"},{"key":"251_CR25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40262-015-0251-9","volume":"54","author":"CN Lim","year":"2015","unstructured":"Lim CN, Salem AH. A semi-mechanistic integrated pharmacokinetic\/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. Clin Pharm. 2015;54:963\u201373.","journal-title":"Clin Pharm"},{"key":"251_CR26","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1124\/jpet.112.195560","volume":"342","author":"E Romero","year":"2012","unstructured":"Romero E, Velez de Mendizabal N, Cendros JM, Peraire C, Bascompta E, Obach R, et al. Pharmacokinetic\/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer. J Pharm Exp Ther. 2012;342:788\u201398.","journal-title":"J Pharm Exp Ther"},{"key":"251_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1124\/pr.110.002642","volume":"63","author":"JM Beaulieu","year":"2011","unstructured":"Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharm Rev. 2011;63:182\u2013217.","journal-title":"Pharm Rev"},{"key":"251_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","volume":"78","author":"C Missale","year":"1998","unstructured":"Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998;78:189\u2013225.","journal-title":"Physiol Rev"},{"key":"251_CR29","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s11095-016-2071-5","volume":"34","author":"F Hao","year":"2017","unstructured":"Hao F, Wang S, Zhu X, Xue J, Li J, Wang L, et al. Pharmacokinetic-pharmacodynamic modeling of the anti-tumor effect of sunitinib combined with dopamine in the human non-small cell lung cancer xenograft. Pharm Res. 2017;34:408\u201318.","journal-title":"Pharm Res"},{"key":"251_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41401-018-0006-x","volume":"40","author":"YH Ma","year":"2019","unstructured":"Ma YH, Wang SY, Ren YP, Li J, Guo TJ, Lu W, et al. Antitumor effect of axitinib combined with dopamine and PK-PD modeling in the treatment of human breast cancer xenograft. Acta Pharm Sin. 2019;40:243\u201356.","journal-title":"Acta Pharm Sin"},{"key":"251_CR31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/j.1875-9114.1989.tb04142.x","volume":"9","author":"V Bhatt-Mehta","year":"1989","unstructured":"Bhatt-Mehta V, Nahata MC. Dopamine and dobutamine in pediatric therapy. Pharmacotherapy. 1989;9:303\u201314.","journal-title":"Pharmacotherapy"},{"key":"251_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0306-3623(82)90088-X","volume":"13","author":"SE O\u2019Connor","year":"1982","unstructured":"O\u2019Connor SE, Brown RA. The pharmacology of sulpiride-a dopamine receptor antagonist. Gen Pharm. 1982;13:185\u201393.","journal-title":"Gen Pharm"},{"key":"251_CR33","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/j.1875-9114.1986.tb03492.x","volume":"6","author":"JF Dasta","year":"1986","unstructured":"Dasta JF, Kirby MG. Pharmacology and therapeutic use of low-dose dopamine. Pharmacotherapy. 1986;6:304\u201310.","journal-title":"Pharmacotherapy"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0251-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0251-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0251-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:02Z","timestamp":1684616522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-019-0251-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,5]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["251"],"URL":"https:\/\/doi.org\/10.1038\/s41401-019-0251-7","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,5]]},"assertion":[{"value":"20 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}